214 related articles for article (PubMed ID: 34977245)
1. Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives.
Ghourichay MP; Kiaie SH; Nokhodchi A; Javadzadeh Y
Biomed Res Int; 2021; 2021():6618934. PubMed ID: 34977245
[TBL] [Abstract][Full Text] [Related]
2. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
Al-Khattawi A; Mohammed AR
Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
[TBL] [Abstract][Full Text] [Related]
3. New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook.
Elwerfalli AM; Ghanchi Z; Rashid F; Alany RG; ElShaer A
Curr Drug Deliv; 2015; 12(6):652-67. PubMed ID: 25760951
[TBL] [Abstract][Full Text] [Related]
4. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
Agiba AM; Abdel-Hamid S; Nasr M; Geneidi AS
Curr Drug Deliv; 2018 Feb; 15(2):267-277. PubMed ID: 28322163
[TBL] [Abstract][Full Text] [Related]
5. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
Cantor SL; Khan MA; Gupta A
Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
[TBL] [Abstract][Full Text] [Related]
6. Oral Disintegrating Tablets - An Updated Patent Perspective.
Sharma S; Singh K
Recent Pat Drug Deliv Formul; 2020; 14(3):166-190. PubMed ID: 33231150
[TBL] [Abstract][Full Text] [Related]
7. Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use.
Comoglu T; Dilek Ozyilmaz E
Pharm Dev Technol; 2019 Sep; 24(7):902-914. PubMed ID: 31215850
[TBL] [Abstract][Full Text] [Related]
8. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
Mostafa HF; Ibrahim MA; Sakr A
Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
[TBL] [Abstract][Full Text] [Related]
9. Compressed orally disintegrating tablets: excipients evolution and formulation strategies.
Al-khattawi A; Mohammed AR
Expert Opin Drug Deliv; 2013 May; 10(5):651-63. PubMed ID: 23387409
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the buccal and gastric transit of orally disintegrating tablets in humans using gamma scintigraphy.
Kambayashi A; Sako K; Kondo H
Int J Pharm; 2020 Feb; 576():118937. PubMed ID: 31816352
[TBL] [Abstract][Full Text] [Related]
11. [Orally disintegrating tablets--advantages and drawbacks].
Tho I
Tidsskr Nor Laegeforen; 2012 Feb; 132(4):424-5. PubMed ID: 22353836
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets.
Gulsun T; Akdag Y; Izat N; Cetin M; Oner L; Sahin S
Pharm Dev Technol; 2020 Oct; 25(8):999-1009. PubMed ID: 32431206
[TBL] [Abstract][Full Text] [Related]
13. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
[TBL] [Abstract][Full Text] [Related]
14. New advances in the characterization of lyophilised orally disintegrating tablets.
Vanbillemont B; Everaert H; De Beer T
Int J Pharm; 2020 Apr; 579():119153. PubMed ID: 32084575
[TBL] [Abstract][Full Text] [Related]
15. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
Moqbel HA; ElMeshad AN; El-Nabarawi MA
Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
[TBL] [Abstract][Full Text] [Related]
16. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
[TBL] [Abstract][Full Text] [Related]
17. On the BCS biowaivers of orally disintegrating tablets.
García-Arieta A; Gordon J
Eur J Pharm Sci; 2015 Jan; 66():107-8. PubMed ID: 25459529
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
[TBL] [Abstract][Full Text] [Related]
19. Recent patents and trends in orally disintegrating tablets.
AlHusban FA; El-Shaer AM; Jones RJ; Mohammed AR
Recent Pat Drug Deliv Formul; 2010 Nov; 4(3):178-97. PubMed ID: 20626334
[TBL] [Abstract][Full Text] [Related]
20. Preparation and evaluation of an orally fast disintegrating tablet formulation containing a hydrophobic drug.
Comoglu T; Unal B
Pharm Dev Technol; 2015 Jan; 20(1):60-4. PubMed ID: 24295202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
